Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.
Caroline GronnierChristophe MarietteCôme LepageCarole MonterymardMarine JaryAurélie FerruMathieu BaconnierXavier AdhouteDavid TavanHervé PerrierVéronique Guerin-MeyerCédric LecailleNathalie Bonichon-LamichhaneDidier PillonOana CojocarasuJoëlle EgreteauXavier Benoit D'journoLaétitia DahanChristophe LocherPatrick TexereauDenis ColletPierre MichelMeher Ben AbdelghaniRosine GuimbaudMarie MullerOlivier BoucheGuillaume PiessenPublished in: Cancers (2023)
Adding cetuximab to the NCT regimen in operable G/GEJ adenocarcinomas is safe, but did not show enough efficacy in the present study to meet the primary endpoint (NCT01360086).